

Diana Romero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9316989/publications.pdf>

Version: 2024-02-01

58
papers

196
citations

1478505

6
h-index

1199594

12
g-index

59
all docs

59
docs citations

59
times ranked

540
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 says goodbye, TIM-3 says hello. Nature Reviews Clinical Oncology, 2016, 13, 203-203.	27.6	50
2	Oncolytic viruses prime antitumour immunity. Nature Reviews Clinical Oncology, 2018, 15, 135-135.	27.6	17
3	PALOMA-2 " hope beyond the threshold. Nature Reviews Clinical Oncology, 2017, 14, 1-1.	27.6	11
4	Tracking ctDNA to evaluate relapse risk. Nature Reviews Clinical Oncology, 2015, 12, 624-624.	27.6	9
5	Metronomic chemotherapy for elderly and/or frail patients. Nature Reviews Clinical Oncology, 2018, 15, 266-266.	27.6	9
6	Platelets to the rescue. Nature Reviews Clinical Oncology, 2017, 14, 140-140.	27.6	8
7	Favourable outcomes with CAR T cells. Nature Reviews Clinical Oncology, 2018, 15, 65-65.	27.6	7
8	CTC heterogeneity is dynamic. Nature Reviews Clinical Oncology, 2016, 13, 654-654.	27.6	6
9	CAR T cells ready to go mainstream. Nature Reviews Clinical Oncology, 2016, 13, 397-397.	27.6	6
10	Nivolumab" an effective second-line treatment for NSCLC. Nature Reviews Clinical Oncology, 2015, 12, 685-685.	27.6	5
11	Atezolizumab becomes POPLAR. Nature Reviews Clinical Oncology, 2016, 13, 266-266.	27.6	5
12	Precision or imprecision medicine?. Nature Reviews Clinical Oncology, 2016, 13, 713-713.	27.6	5
13	Treatment choice " size matters. Nature Reviews Clinical Oncology, 2016, 13, 66-66.	27.6	4
14	Genomic information improves risk prediction. Nature Reviews Urology, 2018, 15, 68-68.	3.8	4
15	Cytarabine " new standard of care for MCL. Nature Reviews Clinical Oncology, 2016, 13, 464-465.	27.6	3
16	MRD assessment " guiding decisions for patients with AML. Nature Reviews Clinical Oncology, 2016, 13, 136-136.	27.6	3
17	Eribulin " a welcomed advance. Nature Reviews Clinical Oncology, 2016, 13, 204-204.	27.6	3
18	Oesophageal cancer " not all alike. Nature Reviews Clinical Oncology, 2017, 14, 138-138.	27.6	3

#	ARTICLE	IF	CITATIONS
19	KEYNOTE-001 " combo improves melody. Nature Reviews Clinical Oncology, 2017, 14, 393-393.	27.6	3
20	After ibrutinib, CAR T cells induce responses. Nature Reviews Clinical Oncology, 2017, 14, 588-588.	27.6	3
21	Keeping aFLOaT with new combination. Nature Reviews Clinical Oncology, 2017, 14, 4-4.	27.6	3
22	Inhibition of TGF β 2 enhances immune-checkpoint blockade. Nature Reviews Clinical Oncology, 2018, 15, 201-201.	27.6	3
23	Benefit of nectin-4 targeting with enfortumab vedotin confirmed. Nature Reviews Urology, 2021, 18, 190-190.	3.8	3
24	ETV6 germline mutation " a risk for ALL. Nature Reviews Clinical Oncology, 2016, 13, 4-4.	27.6	2
25	Idelalisib for CLL " risky benefit. Nature Reviews Clinical Oncology, 2017, 14, 199-199.	27.6	2
26	A CAR T-cell recipe for success. Nature Reviews Clinical Oncology, 2017, 14, 330-330.	27.6	2
27	DDR signature to predict response to ICI. Nature Reviews Clinical Oncology, 2018, 15, 346-346.	27.6	2
28	Time for adjuvant vemurafenib?. Nature Reviews Clinical Oncology, 2018, 15, 265-265.	27.6	2
29	Nice to see you " evolving MHC "peptide presentation. Nature Reviews Clinical Oncology, 2018, 15, 5-5.	27.6	2
30	Rolapitant"a new and safer antiemetic agent. Nature Reviews Clinical Oncology, 2015, 12, 562-562.	27.6	1
31	Promising results of BCL2 inhibition. Nature Reviews Clinical Oncology, 2015, 12, 504-504.	27.6	1
32	Improvements with daratumumab. Nature Reviews Clinical Oncology, 2016, 13, 592-592.	27.6	1
33	Dual targeting to defeat resistance. Nature Reviews Clinical Oncology, 2017, 14, 328-328.	27.6	1
34	Benefit with anti-PD-L1. Nature Reviews Clinical Oncology, 2017, 14, 71-71.	27.6	1
35	Extended EFS with rituximab. Nature Reviews Clinical Oncology, 2017, 14, 714-714.	27.6	1
36	Reality check for nivolumab in advanced-stage melanoma. Nature Reviews Clinical Oncology, 2017, 14, 525-525.	27.6	1

#	ARTICLE	IF	CITATIONS
37	Tracing stem cells in oligodendroglioma. Nature Reviews Clinical Oncology, 2017, 14, 3-3.	27.6	1
38	CheckMate 214 â€” a winning combination?. Nature Reviews Clinical Oncology, 2018, 15, 343-343.	27.6	1
39	Genomic information improves risk prediction. Nature Reviews Clinical Oncology, 2018, 15, 66-67.	27.6	1
40	Relying on quality over quantity. Nature Reviews Clinical Oncology, 2018, 15, 7-7.	27.6	1
41	mDCFâ€”new standard-of-care?. Nature Reviews Clinical Oncology, 2015, 12, 686-686.	27.6	0
42	Improving prediction of relapse risk. Nature Reviews Clinical Oncology, 2015, 12, 564-564.	27.6	0
43	Chemoresistance â€” a little help from friends. Nature Reviews Clinical Oncology, 2016, 13, 329-329.	27.6	0
44	Dressed to ImpRESs. Nature Reviews Clinical Oncology, 2016, 13, 263-263.	27.6	0
45	Here or there, PD-L1 can be anywhere. Nature Reviews Clinical Oncology, 2016, 13, 530-530.	27.6	0
46	High-risk SMM â€” early action required. Nature Reviews Clinical Oncology, 2016, 13, 529-529.	27.6	0
47	Follow your PET for guidance. Nature Reviews Clinical Oncology, 2016, 13, 463-463.	27.6	0
48	TOURMALINE â€” new gem unearthed in the MM treatment landscape. Nature Reviews Clinical Oncology, 2016, 13, 398-398.	27.6	0
49	Divergence shapes recurrence. Nature Reviews Clinical Oncology, 2016, 13, 136-136.	27.6	0
50	Targeted agents: efficacy RESONATEs better with fine tuning. Nature Reviews Clinical Oncology, 2016, 13, 63-63.	27.6	0
51	Fitness depends on KRAS imbalance. Nature Reviews Clinical Oncology, 2017, 14, 262-263.	27.6	0
52	Tracing tumour evolution. Nature Reviews Clinical Oncology, 2017, 14, 391-391.	27.6	0
53	Olaparib improves PFS. Nature Reviews Clinical Oncology, 2017, 14, 460-460.	27.6	0
54	Unravelling intertwined second-line options. Nature Reviews Clinical Oncology, 2017, 14, 197-197.	27.6	0

#	ARTICLE	IF	CITATIONS
55	Importantly, less is effective. Nature Reviews Clinical Oncology, 2017, 14, 585-585.	27.6	0
56	Establishing a family tree. Nature Reviews Clinical Oncology, 2017, 14, 525-525.	27.6	0
57	Feasible mutation-targeted therapy. Nature Reviews Clinical Oncology, 2017, 14, 460-460.	27.6	0
58	Improved pain management. Nature Reviews Clinical Oncology, 2018, 15, 346-346.	27.6	0